Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2025-05-20 00:00:00 ET · period of report 2025-05-16 · accession 0001415889-25-013816 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-20 | 2025-05-16 | LXEO | See Tai Sandi | Chief Development Off | S - Sale | $2.77 | -367 | 59.2K | -0.6% | -$1,017 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-16 | S | D | 367 | $2.77 | 59,242 | D | — | — | (F2) Includes 50,178 RSUs. |